103.50EUR-0.77%Mkt Cap: 7.85B EURP/E: —Last update: 2026-05-14
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-31.72
PEG—
P/B17.09
P/S1718.55
EV/EBITDA-29.98
EV/Revenue1607.22
EPS (TTM)-4.83
EPS (Forward)-3.12
Cash Flow & Leverage
FCF Yield-1.51%
FCF Margin-2588.99%
Operating CF-161.13M EUR
CapEx (TTM)142.00K EUR
Net Debt/EBITDA2.03
Net Debt-498.29M EUR
Technical
SMA 50100.98 (+2.5%)
SMA 20092.58 (+11.8%)
Beta-0.19
S&P 52W Chg24.23%
Avg Vol (30d)116.95K
Avg Vol (10d)130.34K
Technical Indicators
RSI (14)52.4
MACD1.1016
MACD Signal0.6788
MACD Hist.+0.4229
BB Upper110.46 EUR
BB Middle101.33 EUR
BB Lower92.21 EUR
BB Width18.01%
ATR (14)5.169 EUR
Vol Ratio (20d)1.18x
52W Range
5.00078% of range132.00
52W High132.00 EUR
52W Low5.000 EUR
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin-3743.36%
ROE-73.84%
ROA-57.52%
Revenue Growth-55.40%
Earnings Growth—
Balance Sheet
Debt/Equity0.00
Current Ratio8.75
Quick Ratio8.58
Book Value/Sh5.796 EUR
Cash/Share6.698 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.79.29M
Float64.14M
Insiders1.04%
Institutions50.74%
Analyst Consensus
Rating—
Target (Mean)121.48 EUR
Target Range63.00 EUR – 160.00 EUR
# Analysts7
Company
Market Cap7.85B EUR
Enterprise Value7.34B EUR
Revenue (TTM)4.57M EUR
Gross Profit4.57M EUR
Net Income (TTM)-336.10M EUR
Revenue/Share0.0660 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees69
Last Price103.50 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012333284